Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Crohns Colitis ; 10(6): 663-9, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26783346

ABSTRACT

AIMS: The objective of the current study was to compare two patient assessment strategies using colonoscopy and MRI alternatively as first- and second-line examinations. METHODS: Clinical data, endoscopy and magnetic resonance imaging (MRI) examinations of 100 patients diagnosed with ileocolonic Crohn's disease (CD) performed within 1 week were blindly reviewed by 4 clinical investigators. Two investigators evaluated MRI followed by colonoscopy for 50 cases and the same examinations in reverse order for another 50 cases; the other 2 investigators evaluated the same cases switching the order of examinations. The assessments included the likelihood of the presence of inflammation, stenosis, fistula and abscess, and therapeutic recommendations. RESULTS: Information from the first examination was considered sufficient for management in 80% of cases for MRI and only 34% of cases for colonoscopy (p < 0.001). Adding MRI to the information from colonoscopy changed the clinicians' confidence grade in a higher proportion of patients than adding colonoscopy to information from MRI for the diagnosis of disease activity (10 vs 4%, p = 0.03), stenosis (25 vs 9%, p < 0.001), fistula (31 vs 0%, p < 0.001) and internal abscess (27 vs 0%, p < 0.001). Indications for anti-tumour necrosis factor (TNF) therapy (51 vs 37%, F = 0.006), and surgery (12 vs 5%, F = 0.019) were more frequent after MRI than after colonoscopy as first examination. As a second examination, MRI led to change in therapy in a higher proportion of patients than colonoscopy (28 vs 8%, p < 0.001). CONCLUSIONS: In CD, information provided by MRI has a higher impact on patient management than colonoscopy and may be considered as a first-line examination for CD assessment.


Subject(s)
Colonoscopy , Crohn Disease/diagnostic imaging , Magnetic Resonance Imaging , Adult , Anti-Inflammatory Agents/therapeutic use , Clinical Decision-Making , Crohn Disease/drug therapy , Female , Humans , Logistic Models , Male , Middle Aged , Odds Ratio , Prospective Studies , Single-Blind Method
2.
Inflamm Bowel Dis ; 18(5): 812-7, 2012 May.
Article in English | MEDLINE | ID: mdl-21826765

ABSTRACT

BACKGROUND: Despite medical therapy, 30% of patients with ulcerative colitis (UC) need to undergo surgery. Around 50% of patients with proctocolectomy with ileal pouch-anal anastomosis (IPAA) develop complications of the pouch. Clinical evidence for the use of infliximab (IFX) in refractory pouchitis is limited. The aim of this study was to report efficacy of IFX in these patients. METHODS: A retrospective, multicenter study was designed. Patients older than 18 years with chronic refractory pouchitis treated with IFX (5 mg/kg) were included. Short-term IFX efficacy was evaluated at week 8 and mid-term efficacy at weeks 26 and 52. Complete response was defined as cessation of diarrhea and urgency and partial response as marked clinical improvement but persisting symptoms. The modified Pouchitis Disease Activity Index (mPDAI) without endoscopy was calculated when available. RESULTS: Thirty-three consecutive UC patients with chronic refractory pouchitis were included (18 male, mean age 45 years, range 21-67). At week 8, 21% patients achieved complete response and 63% showed partial clinical response. At weeks 26 and 52, 33% and 27% achieved complete response and 33% and 18% showed partial clinical response, respectively. Thirteen patients (39%) withdrew treatment (four for lack of efficacy, four for loss of response and five for adverse events). None of the potential factors analyzed had an influence on response to IFX. CONCLUSIONS: IFX was effective in the short- and mid-term in patients with chronic refractory pouchitis. However, medication had to be discontinued in a high number of patients.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Colitis, Ulcerative/complications , Gastrointestinal Agents/therapeutic use , Postoperative Complications , Pouchitis/drug therapy , Adult , Aged , Chronic Disease , Colitis, Ulcerative/surgery , Female , Follow-Up Studies , Humans , Infliximab , Male , Middle Aged , Pouchitis/diagnosis , Pouchitis/etiology , Proctocolectomy, Restorative , Remission Induction , Retrospective Studies , Treatment Outcome , Young Adult
3.
Aliment Pharmacol Ther ; 32(8): 939-52, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20804451

ABSTRACT

BACKGROUND: Drugs available for the treatment of inflammatory bowel disease fail to induce and maintain remission in a significant number of patients. AIM: To assess the value of stem cell therapies for treatment of inflammatory bowel disease based on published studies. METHODS: Publications were identified through a MEDLINE search using the Medical Subject Heading terms: inflammatory bowel diseases, or Crohn's disease, or ulcerative colitis, and stem cell, or stromal cell or transplant. RESULTS: Haematopoietic stem cell therapy as a primary treatment for inflammatory bowel disease was originally supported by animal experiments, and by remissions in patients undergoing transplant for haematological disorders. Later, transplantation specifically performed for patients with refractory Crohn's disease showed long-lasting clinical remission and healing of inflammatory intestinal lesions. Use of autologous nonmyeloablative regimens and concentration of the procedures in centres with large experience are key in reducing treatment-related mortality. Initial trials of mesenchymal stem cell therapy with local injection in Crohn's perianal fistulas had positive results. CONCLUSIONS: Autologous haematopoietic stem cell transplant changes the natural course of Crohn's disease, and may be a therapeutic option in patients with refractory disease if surgery is not feasible due to disease location or extension.


Subject(s)
Hematopoietic Stem Cell Transplantation , Inflammatory Bowel Diseases/therapy , Mesenchymal Stem Cell Transplantation , Adult , Animals , Disease Models, Animal , Female , Humans , Male , Middle Aged , Transplantation, Autologous , Young Adult
4.
Gut ; 58(8): 1113-20, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19136510

ABSTRACT

OBJECTIVE: Assessment of disease extension and activity is crucial to guide treatment in Crohn's disease. The objective of the current cross-sectional study was to determine the accuracy of MR for this assessment. DESIGN: 50 patients with clinically active (n = 35) or inactive (n = 15) Crohn's disease underwent ileocolonoscopy (reference standard) and MR. T2-weighted and precontrast and postcontrast-enhanced T1-weighted sequences were acquired. Endoscopic activity was evaluated by CDEIS (Crohn's Disease Endoscopic Index of Severity); in addition endoscopic lesions were classified as absent, mild (inflammation without ulcers) or severe (presence of ulceration). RESULTS: The comparison of intestinal segments with absent, mild and severe inflammation demonstrated a progressive and significant (p<0.001) increase in the following MR parameters: wall thickness, postcontrast wall signal intensity, relative contrast enhancement, presence of oedema, ulcers, pseudopolyps and lymph node enlargement. Independent predictors for CDEIS in a segment were wall thickness (p = 0.007), relative contrast enhancement (p = 0.01), presence of oedema (p = 0.02) and presence of ulcers at MR (p = 0.003). There was a significant correlation (r = 0.82, p<0.001) between the CDEIS of the segment and the MR index calculated according to the logistic regression analysis coefficients. The MR index had a high accuracy for the detection of disease activity (area under the receiver operating characteristic (ROC) curve 0.891, sensitivity 0.81, specificity 0.89) and for the detection of ulcerative lesions (area under the ROC curve 0.978, sensitivity 0.95, specificity 0.91) in the colon and terminal ileum. CONCLUSION: The accuracy of MR for detecting disease activity and assessing severity brings about the possibility of using MR as an alternative to endoscopy in the evaluation of ileocolonic Crohn's disease.


Subject(s)
Colonic Diseases/diagnosis , Crohn Disease/diagnosis , Ileal Diseases/diagnosis , Adult , Colon/pathology , Colonoscopy , Cross-Sectional Studies , Female , Humans , Ileum/pathology , Image Interpretation, Computer-Assisted/methods , Magnetic Resonance Imaging/methods , Male , Severity of Illness Index , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...